Open Access

Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature

  • Authors:
    • Lei Song
    • Dejian Pan
    • Rengui Zhou
  • View Affiliations

  • Published online on: August 24, 2020     https://doi.org/10.3892/mco.2020.2124
  • Article Number: 54
  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The main therapeutic strategy for metastatic Myxofibrosarcoma (MFS) is palliative chemotherapy. A number of studies have demonstrated that anti‑angiogenic therapy and immunotherapy could improve the survival rate of patients with metastases. However, the effectiveness of the combination of anti‑angiogenic therapy and immunotherapy for the therapy of MFS is undetermined. The current study reports a case of metastatic myxofibrosarcoma that was treated with combination Nivolumab (monoclonal antibody, PD‑1 inhibitor) and Bevacizumab (monoclonal antibody, anti‑VEGF) after progression from the single use of Nivolumab. The aim of the current study is to assess the efficacy and safety of Nivolumab and Bevacizumab for metastatic myxofibrosarcoma and to review the literature. Up to the termination of the follow‑up, the patient achieved a partial response for 16 months, had an overall survival for over 29 months since the metastasis and demonstrated a sustained benefit from treatment. The most frequent adverse events were fatigue, abnormality of Alanine aminotransferase (ALT), hypertension and proteinuria. Nivolumab and Bevacizumab treatment indicate beneficial clinical effects and are indicated to be safe to use in patients with metastatic myxofibrosarcoma.
View Figures
View References

Related Articles

Journal Cover

November-2020
Volume 13 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song L, Pan D and Zhou R: Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature. Mol Clin Oncol 13: 54, 2020.
APA
Song, L., Pan, D., & Zhou, R. (2020). Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature. Molecular and Clinical Oncology, 13, 54. https://doi.org/10.3892/mco.2020.2124
MLA
Song, L., Pan, D., Zhou, R."Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature". Molecular and Clinical Oncology 13.5 (2020): 54.
Chicago
Song, L., Pan, D., Zhou, R."Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature". Molecular and Clinical Oncology 13, no. 5 (2020): 54. https://doi.org/10.3892/mco.2020.2124